Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Jose Luis Pelaez Inc/DigitalVision via Getty Images When I last wrote about Terns Pharmaceuticals, Inc. (NASDAQ:TERN) in July 2023, the company was in clinical trials with a leukemia drug and a drug for liver disease, and I rated it a buy on its prospects in those disease areas. Now TERN has reported results from a four-week study of its oral GLP-1 receptor agonist (TERN601), showing impressive weight loss, meaning the company might have itself a drug for obesity. This article takes a look at the weight los ...